These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21441850)

  • 1. Why valganciclovir should not be indicated for liver recipients and high-dose acyclovir should not be removed from international cytomegalovirus guidelines.
    Kalil AC; Florescu DF
    Transplantation; 2011 Jan; 91(1):e8-9; author reply e10. PubMed ID: 21441850
    [No Abstract]   [Full Text] [Related]  

  • 2. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
    McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST
    Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients.
    Reischig T; Prucha M; Sedlackova L; Lysak D; Jindra P; Bouda M; Matejovic M
    Antivir Ther; 2011; 16(8):1227-35. PubMed ID: 22155904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
    Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
    Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of pre-emptive or prophylactic valganciclovir therapy for prevention of cytomegalovirus infection in renal transplantation.
    Santos RD; Brennan DC
    J Am Soc Nephrol; 2012 Sep; 23(9):1446-8. PubMed ID: 22878958
    [No Abstract]   [Full Text] [Related]  

  • 7. Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation.
    Avidan YP; Paul M; Rahamimov R; Bishara J; Samra Z; Edna S; Mor E
    J Infect; 2008 Sep; 57(3):236-40. PubMed ID: 18674820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-cytomegalovirus prophylaxis in solid-organ transplant recipients.
    Falagas ME; Vardakas KZ
    Clin Microbiol Infect; 2006 Jul; 12(7):603-5. PubMed ID: 16774555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is low-dose valganciclovir the same as appropriate-dose valganciclovir?
    Pescovitz MD
    Transplantation; 2007 Jul; 84(1):126; author reply 126-7. PubMed ID: 17627250
    [No Abstract]   [Full Text] [Related]  

  • 11. Does high-dose prophylactic acyclovir add benefit in allogeneic marrow transplant recipients receiving prophylactic or preemptive ganciclovir?
    de la Cámara R; Fernández-Rañada JM
    J Infect Dis; 1999 Aug; 180(2):571-4. PubMed ID: 10395887
    [No Abstract]   [Full Text] [Related]  

  • 12. Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients.
    Clark BS; Chang IF; Karpen SJ; Herrera L; Scott JD; Bristow LJ; Quirós-Tejeira RE; Goss JA
    Transplantation; 2004 May; 77(9):1480. PubMed ID: 15167619
    [No Abstract]   [Full Text] [Related]  

  • 13. Low-dose valganciclovir for cytomegalovirus prophylaxis in organ transplantation: is less really more?
    Avery RK
    Clin Infect Dis; 2011 Feb; 52(3):322-4. PubMed ID: 21190935
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
    Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK; Eid AJ; Pedersen RA; Dierkhising RA; Kremers WK; Patel R; Razonable RR
    Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation.
    Lapidus-Krol E; Shapiro R; Amir J; Davidovits M; Steinberg R; Mor E; Avitzur Y
    Pediatr Transplant; 2010 Sep; 14(6):753-60. PubMed ID: 20477976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Question of using valganciclovir for cytomegalovirus (CMV) infection prophylaxis in post-liver transplant recipients.
    Jain A; Mohanka R; Orloff M; Abt P; Ryan C; Bozorgzadeh A
    Liver Transpl; 2006 Jun; 12(6):1020-1; author reply 1022-3. PubMed ID: 16721778
    [No Abstract]   [Full Text] [Related]  

  • 19. Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?
    Smolej L
    Blood; 2008 Sep; 112(5):2167. PubMed ID: 18725576
    [No Abstract]   [Full Text] [Related]  

  • 20. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
    Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
    J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.